Garzone Pamela reported grant involving 18,900 shares of Cue Biopharma, Inc. at $0.00 for $0 on Jul 9, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Aug 28, 2026

Facts from the filing

Form 4/A · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
18,900Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
18,900Direct
Trade date
Jul 9, 2026Grant
Filed
Aug 28, 2026, 5:04 PM ET50-day reporting delay
Accession
0001974756-26-000006Code A · Transaction 118220
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

This amendment is separate from the original filing. It may contain only changed rows. Read both SEC reports.

Filing warnings

Notes recorded with this filing
2 warnings
amended filingThis transaction comes from an amended Form 4 filing.
delayed filingThe filing was reported 50 calendar days after the transaction date.

CUE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CUE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −14%1w ago +1.4%1d ago +27%
Returns since7d −1.6%30d +13%90d180d1y

Footnotes in full

F1: This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date.